Implications of the FDA Approval of Subcutaneous Amivantamab in EGFR-Mutated NSCLC

Luis Raez, MD, FACP, FCCP, and Alexander I Spira MD, PhD, FACP, FASCO, discuss the clinical implications of the FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) and updated 4-week dosing in the treatment of patients with EGFR-mutated non–small cell lung cancer. Spira reviews pharmacokinetic, efficacy, and safety data from PALOMA-3 comparing the subcutaneous and intravenous formulations. Raez considers how reduced chair time and once-monthly dosing may improve patient convenience, adherence, and shared decision-making in routine practice.